Subscribe to RSS
DOI: 10.1055/s-0032-1315031
Antikoagulantion bei Vorhofflimmern: Neue Substanzen – für wen (nicht)?
Anticoagulation for Atrial Fibrillation: New Oral Anticoagulants?Publication History
Publication Date:
15 August 2012 (online)
Zusammenfassung
Mit Dabigatran und Rivaroxaban stehen derzeit 2 zugelassene neue orale Antikoagulanzien zur Therapie von Vorhofflimmern zur Verfügung, und die Zulassung von Apixaban ist absehbar. Alle Substanzen haben ein günstigeres pharmakologisches Profil als Vitamin-K-Antagonisten, bedürfen in der Regel keiner laborchemischen Überwachung und sind sicherer. Insbesondere reduzieren die neuen oralen Antikoagulanzien die Rate intrakranieller Blutungen. Sowohl Dabigatran als auch Apixaban senken die Häufigkeit von Schlaganfällen signifikant. Dabigatran in einer Dosis von 2 × 150 mg senkt die Raten ischämischer Schlaganfälle, während Apixaban die Gesamtmortalität senkt. Rivaroxaban hat den Vorteil der Einmalgabe und kann bis zu einer CrCl von 15 ml/min gegeben werden.
Abstract
Dabigatran and rivaroxaban are 2 newly licensed oral anticoagulants for the treatment of atrial fibrillation. It is expected that apixaban will also soon be approved for clinical use. All of these substances have a more favorable pharmacological profile than vitamin K antagonists. They generally do not require routine laboratory monitoring and are safer. The new oral anticoagulants were found to reduce rates of intracranial bleeding. Both dabigatran and apixaban significantly reduced the incidence of stroke. Dabigatran administered at a dosage of 2 × 150 mg reduced the rates of ischemic stroke, while apixaban reduced overall mortality. Rivaroxaban has the advantage that it is administered as a single dose and can be administered up to a CrCl of 15 ml/min.
-
Literatur
- 1 Fuster V, Rydeʼn LE, Cannom DS et al. ACC/AHA/ESC2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745
- 2 Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953
- 3 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988
- 4 Jørgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen stroke study. Stroke 1996; 27: 1765-1769
- 5 Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996; 27: 1760-1764
- 6 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
- 7 Birman-Deych E, Radford MJ, Nilasena DS et al. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke 2006; 37: 1070-1074
- 8 Jones M, McEwan P, Morgan CL et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477
- 9 Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037
- 10 Katnelson M, Sacco RL, Moscucci M et al. Progress for stroke prevention with atrial fibrillation. Emergence of alternative oral anticoagulants. Circulation 2012; 125: 1577-1583
- 11 Stangier J, Eriksson BI, Dahl OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor, dabigatran etexilate, in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563
- 12 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
- 13 Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial. Circulation 2012; 125: 669-676
- 14 Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012; 26: 27-32
- 15 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
- 16 De Caterina R, Husted S, Wallentin L. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. ESC working group on thrombosis – task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012; 59: 1413-1425
- 17 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Eng J Med 2011; 364: 806-817
- 18 Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-339
- 19 Granger CB, Alexander JH, Mc Murray JJV et al. for the ARISTOTLE committees and investigators. Apixaban verus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
- 20 Eerenberg ES, Kamphuisen PW, Sifpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579
- 21 Marinigh R, Lane DA, Lip GYH. Severe renal impairment and stroke prevention in atrial fibrillation. J Am Coll Cardiol 2011; 57: 1339-1348
- 22 Fox KAA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairement. Eur Heart J 2011; 32: 2387-2394
- 23 Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136
- 24 Omran H, Bauersachs R, Rübenacker S et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicenter BNK onle Bridging Registry (BORDER). Thromb Haemost 2012; Apr 26; 108 (epub ahead of print)